exagamglogene autotemcel Casgevy
Selected indexed studies
- Exagamglogene Autotemcel for Severe Sickle Cell Disease. (N Engl J Med, 2024) [PMID:38661449]
- Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. (N Engl J Med, 2024) [PMID:38657265]
- ** (, 2025) [PMID:40758800]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Exagamglogene Autotemcel for Severe Sickle Cell Disease. (2024) pubmed
- A roadmap for affordable genetic medicines. (2024) pubmed
- Exagamglogene Autotemcel: First Approval. (2024) pubmed
- Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. (2024) pubmed
- PMID:40758800 (2025) pubmed
- PMID:40424427 (2025) pubmed
- Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) for individuals 12 years and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises (VOC): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). (2024) pubmed
- PMID:39977564 (2025) pubmed
- PMID:39977554 (2025) pubmed
- Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel. (2024) pubmed